NCT05889468

Postpartum ASA and NT-proBNP

The Association Between Postpartum Aspirin Use and NT-proBNP Levels as a Marker for Maternal Health Outcomes.

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 114 (actual)
• Sponsor: Duke University · Academic / Other
• Sex: Female
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

This study is a double-blinded randomized-controlled trial in which patients will be randomized to 81 mg of aspirin or placebo to be continued for 6 weeks' postpartum. The purpose of this study is to compare NT-proBNP levels at the 4-6 week postpartum visit between groups. There is currently no data on the maternal health effects associated with continuation of low-dose aspirin in the postpartum period. This study aims to fill a gap in the knowledge regarding the utility of low-dose aspirin following delivery.

Conditions

• Blood Pressure

Interventions

Type	Name	Description
DRUG	Aspirin 81Mg Ec Tab	Participant may be provided with a 6-week supply of 81 mg of aspirin prior to discharge from the delivery admission.
DRUG	Placebo	Participant may be provided with a 6-week supply of placebo to discharge from the delivery admission.

Timeline

• Start date: 2023-07-01
• Primary completion: 2024-05-21
• Completion: 2024-05-21
• First posted: 2023-06-05
• Last updated: 2025-06-04
• Results posted: 2025-06-04

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study